PIK3CA and neoplasm: Similarly, there was no significant difference in overall survival between patients with or without PIK3CA hotspot mutation in the primary tumor (log-rank p = 0.27; Fig. 3d), nor in the relapse tumor (log-rank p = 0.3; Fig. 3e), or in any tumor sample (log-rank p = 0.39; Fig. 3f).